University of Abacete Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT01306942
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Complejo Hospitalario Universitario de Albacete

Active Ingredients

Drugs in Phase 2 Trials (3)

dasatinib (sprycel) (1 trial)

paclitaxel (taxol) (1 trial)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3